Pharmacokinetics, N1-glucuronidation, and N4-acetylation of sulfa-6- monomethoxine in humans

TB Vree, EW Beneken Kolmer, YA Hekster, M Shimoda, M Ono and T Miura

Department of Clinical Pharmacy, Academic Hospital Nijmegen Sint- Radboud, The Netherlands.

Sulfamonomethoxine (S) is metabolized by O-dealkylation, N4- acetylation, and N1-glucuronidation. In humans, only N1-glucuronidation (12%) and N4-acetylation (36%) takes place. The N1-glucuronide is directly measured by HPLC. When N4-acetylsulfamonomethoxine (N4) is administered as the parent drug, N1-glucuronidation does not occur. After an oral dose, fast and slow acetylators show a similar t1/2 for S (25.0 +/- 4.6 hr vs. 29.8 +/- 4.8 hr; p = 0.459), and the t1/2 of the N4-acetyl conjugate is also similar in fast and slow acetylators (25.0 +/- 4.64 hr vs. 29.8 +/- 4.8 hr, p = 0.459). The intrinsic mean residence time of N4 is 7.1 +/- 2.3 hr. The mean total body clearance of S is 5.0 +/- 1.3 ml/min, the renal clearance is 0.84 +/- 0.26 ml/min, and the volume of distribution at steady state is 11.7 +/- 3.4 liters. The renal clearance of N4 is 17.89 +/- 4.19 ml/min. No measurable concentrations of the N1-glucuronide of S are found in plasma. The protein binding of S is 92%. N1-glucuronidation results in an 80% reduction in the protein binding of S (11%). N4 shows a high protein binding of 98%. Approximately 60% of the oral dose of S is excreted in the urine.

Volume 18, Issue 6, pp. 852-858, 11/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				K. Komatsu, K. Ito, Y. Nakajima, S.-i. Kanamitsu, S. Imaoka, Y. Funae, C. E. Green, C. A. Tyson, N. Shimada, and Y. Sugiyama Prediction of in Vivo Drug-Drug Interactions between Tolbutamide and Various Sulfonamides in Humans Based on in Vitro Experiments Drug Metab. Dispos., April 1, 2000; 28(4): 475 - 481. [Abstract] [Full Text]